RT Journal Article
SR Electronic
T1 Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.12.20170282
DO 10.1101/2020.08.12.20170282
A1 Raja Bhattacharya
A1 Rohini Ghosh
A1 Manish Kulshrestha
A1 Sampurna Chowdhury
A1 Rishav Mukherjee
A1 Indranil Ray
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.12.20170282.abstract
AB Objective This study will attempt to explore the demographic profile and outcome in the patients receiving multidisciplinary, personalised approach including use of Broad Spectrum Antivirals - Ivermectin, anti-inflammatory and antioxidants roles of Statins and N-acetyl-cysteine along with Standard of Care (SOC) in hospitalised COVID19 patients in a tertiary care centre.Setting Inpatient departmentParticipants 191 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020 between June 14-28, 2020Main outcome measures The outcome of Interests are:Studying the demographic profile of COVID 19 casesStudy the treatment outcomes in terms of death or discharge in patients receiving Ivermectin+N-acetyl-cysteine+Statin along with Standard of care.Results 148 patients were included in the study. All of them had confirmed COVID19 infection by the rtPCR method. Average age of the patients was 57.57 years (Range = 17 - 88), 49% were male, 51% female. 81% of the patients had at least one or more comorbidities. Most common comorbidities included diabetes (32%), Hypertension (27%),Ischaemic Heart Disease (8%). More comorbidities. The in hospital, Case Fatality Rate was therefore, 1.35 %. The remaining 144 were discharged from the facility after an average 12 days duration of stay.Conclusions Triple therapy with ivermectin + atorvastatin + N-acetylcysteine can be an useful adjunct to standard of care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee approved this observational study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA